Jun 4, 2022
Bristol Myers Boosts Cancer Drug Portfolio With $4.1 Billion Turning Point Deal
Bristol Myers Squibb Co. said on Friday it will acquire drug developer Turning Point Therapeutics Inc. for $4.1 billion in cash to help bolster its arsenal of cancer drugs. Turning Point's lead drug, repotrectinib, targets mutations in certain proteins in ...
NEXT EPISODE
Jun 4, 2022
Retired Lawyer Claims Rolled out COVID Jabs Differ From Those Trialed Before Authorization
PREVIOUS EPISODE